Thank you, Mr. Chair.
Thank you, everybody, for being here today. Your presentations are greatly appreciated, enlightening us and educating us a little more on a lot of the stuff we've heard.
Throughout these meetings we've heard significant responses on issues. One that is concerning to me, and I've heard from most of you today, is the issue of supply chain challenges and risks. I believe Mr. Keon talked about how the movement is slower and more costly. We've heard about potential drug shortages, etc.
I go back to a number of meetings, when I was looking at things a little more closely than I have today, when there was a shortage of Epinephrine, and Diovan, Gabapentin, Carbathol, Cyclosporine, Novamoxin. Many of these drugs are definitely needed by Canadians today. We're seeing shortages of them.
It would be interesting to hear comments. Dr. Neame, I think you mentioned potential supply issues. I'm wondering if you could start. We would then go on to the CGPA.